A phase II clinical trial using anti-NGF antibody, fulranumab, as adjunctive therapy for cancer-related pain found no significant effect on pain intensity via visual analog scale; however, significant improvement on the Brief Pain Inventory subscales suggested improved quality of life (Slatkin et al., 2019). The gene discussed is NGF; the disease is cancer.